Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 403-730-1 | CAS number: 2687-96-9
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
A review was performed of available data and a structural assessment made.Bioaccumulation of parent molecule and its metabolites is considered to be very low as their metabolism half lives are fast to very fast.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
Evidence for systemic availability of the substance comes from several studies in rats with N-(n-dodecyl) pyrrolidinone or its analogue N-(n-octyl)pyrrolidinone. In an a subacute toxicity study with gavage doses of 0, 10, 100, and 1000 mg/kg/day, clinical chemistry and pathological effects were observed at the 1000 mg/kg/day dose levels (Smith, 1989). In a 28-day oral (gavage) study, rats were dosed with 0, 10, 100, or 1,000 mg/kg/day (once daily) of the substance (Smith, 1989). Changes in general health, bodyweight gain, food consumption, organ weights, macroscopic and microscopic pathology and biochemical parameters were apparent in rats receiving 1,000 mg/kg/day of the substance. Furthermore a 90-day dietary feeding study in rats (ISP, 1991) in which rats were dosed with 0, 60, 600, and 10000 mg/kg/day of the analog substance LP100. Systemic toxicity in males and females was noted in the 10000 mg/kg/day group. Changes in body weight gain and food consumption as well as changes in liver weights and some mild hepatocyte hypertrophy was observed in this relatively high dose group.
Considering the chemical structure of the substance, Cyp 450 linked oxidations of the dodecyl-group and of the heterocyclic ring system as well as the oxidative de-alkylation are possible steps in the phase-I metabolism of the substance. In phase-II metabolism, consequent conjugation reactions can be assumed.
Studies on genotoxicity (Lavelle, 1986; Fowler, 1989, Fowler, 1989) were negative. There were no indications of DNA reactivity of the substance or its metabolites under the test conditions.
Bioaccumulation of parent molecule and its metabolites is considered to be very low as their metabolism half lives are fast to very fast.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
